Core Clinical Research

Running trials

• Recruiting

  Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

  NCT07226661· Phase 2· Source

• Recruiting

  A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  NCT06793397· Phase 3· Source

• Active, not recruiting

  An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

  NCT07217860· Phase 3· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

  NCT07172516· Phase 3· Source

• Active, not recruiting

  An Open-Label Study of Azetukalner in Major Depressive Disorder

  NCT06922110· Phase 3· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  NCT06775379· Phase 3· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

  NCT06706674· Phase 3· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

  NCT06372964· Phase 3· Source

• Recruiting

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression3 recruiting
• Autism2 recruiting
• Bipolar disorder2 recruiting
• Schizophrenia1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Source

• Completed

  A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

  NCT06785012· Phase 2· Source

• Completed

  A Study to Test Different Doses of BI 1569912 in People With Depression

  NCT06558344· Phase 2· Source

• Completed

  Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

  NCT06557902· Phase 1· Source

• Completed

  A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

  NCT06254612· Phase 2· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Source

• Completed

  Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

  NCT05536414· Phase 2· Source

• Completed

  A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

  NCT05113771· Phase 2· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

  NCT04846868· Phase 3· Source

• Completed

  A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

  NCT04521478· Phase 2· Source